SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is generating significant investor interest driven by high trading volumes, active momentum in its clinical-stage pipeline, and multiple analyst endorsements from firms like Guggenheim and HC Wainwright. Community discussion is focused on the high-stakes Phase 2 LOTUS trial readout expected in 2026 and ongoing debates regarding the company's financial risk profile versus the potential upside of its immunology platform.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors monitor its resilience amid macroeconomic volatility and ongoing debates surrounding the impact of potential tariff refunds on retail pricing. The community remains focused on Costco's defensive strengths, with frequent discussions centered on its robust membership renewal rates, traffic growth, and valuation relative to the broader consumer staples sector.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a major focal point for traders due to its recent surge in social media volume and discussion surrounding its post-quantum security features. Community members remain polarized, with many debating the impact of institutional-grade infrastructure upgrades and potential regulatory shifts while long-term holders focus on accumulation during significant price volatility.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a major upcoming partnership announcement, with many pointing to a connection with Stellar or a potential collaboration with Ripple/XRP at an upcoming industry event. Investors are actively debating the project's long-term utility in global payroll and real-world adoption, balancing high-conviction sentiment against skepticism regarding its price performance and market volatility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing investor attention as they rotate toward defensive, value-oriented positions amidst broader market volatility. The community is actively debating the fund's resilience, with many investors maintaining a long-term 'buy and hold' strategy despite recent stagnant performance, while others monitor the ETF's sector diversification and dividend growth potential as a reliable hedge.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as the community eagerly awaits definitive biomarker data and regulatory updates regarding an accelerated approval pathway for its ALS candidate, CNM-Au8. Investors are closely monitoring upcoming conference presentations and regulatory milestones, balancing high-conviction long-term sentiment against volatility driven by short interest and recent insider selling activity.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is experiencing heightened volatility and intense community debate as it tests critical support levels around 60k-65k, with traders closely monitoring technical formations like bear flags and head-and-shoulders patterns. While some bulls are looking for a reclaim of key resistance zones to trigger a long-term uptrend, many participants remain cautious, pointing to equity market weakness and potential liquidity risks that could lead to further downside tests.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is currently a focal point for the community due to major structural updates like Mission 70aimed at reducing token inflationand increasing adoption through sovereign subnets in regions like Switzerland and Pakistan. While some users remain skeptical due to historical volatility and the project's long-term performance, many community members are highlighting the real-world utility of platforms like Caffeine.ai and the growing number of canisters as indicators that the network's fundamentals are strengthening for a future recovery.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is capturing significant attention as the firm integrates advanced AI models to automate compliance roles, while simultaneously navigating heightened market scrutiny over its past ties to Jeffrey Epstein and recent leadership resignations. The stock is experiencing intense volatility as investors weigh these corporate headwinds against the firm's strategic expansion into private credit and asset management.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox (BW) is experiencing significant momentum following a major $2.4 billion power infrastructure contract, with community discussions largely focused on its role in providing essential energy solutions for AI data centers. The stock is a primary focal point for investors tracking related holdings like B. Riley (RILY) and Applied Digital (APLD), as participants debate the impact of institutional backing and the potential for a long-term valuation re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.</li><li>Following months of engagement between the company and the FDA, the company subsequently resubmitted its application in October with additional information, data and analyses.</li></ul> Shares of Replimune Group Inc (REPL) closed 11% higher on Thursday as the deadline for the U.S. Food and Drug Administration’s decision on its skin cancer therapy RP1 draws close.The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.<h2 class="st-heading-2">RP1’s Past Issues</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">issued</a> a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, the company subsequently resubmitted its application in October with additional information, data and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that shareholders are setting up to be disappointed like the last time when RP1 was denied approval.<stembedurl>https://www.stocktwits.com/TopCharts/message/649353360</stembedurl>Yet another expressed doubts about the FDA approving the drug, opining that a fresh trial would be needed for the same.<stembedurl>https://www.stocktwits.com/Steve_TheBull_Rogers/message/649347582</stembedurl>According to data from Koyfin, five of the seven analysts covering REPL stock rate it ‘Buy’ or higher while two rate it a ‘Hold’. The 12-month average price target on the stock is $12.86, representing a potential upside of about 53%. &nbsp;<a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-sbac-stock-rallying-today/cZ7UR5SRI8r">Why Is SBAC Stock Rallying Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug

The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10.

Equity

Replimune Group (NASDAQ:REPL) Shares Up 7.2% - Should You Buy?

Replimune Group (NASDAQ:REPL) Trading Up 7.2% - Time to Buy...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two...

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy

IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.

Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL

Boxer Capital Management LLC decreased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 52.5% during the 3rd quarter, according to the company in its most recent filing...

Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL

Braidwell LP raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 550.3% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest REPL News

REPLReplimune Group Inc